Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Provides Clinical Trial Update
ArQule Provides Clinical Trial Update WOBURN, Mass.--(BUSINESS WIRE)--Jan. 16, 2007--ArQule, Inc. (NASDAQ: ARQL) today provided an update on its clinical trials with three compounds: ARQ 197, a proprietary, orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase; ARQ 501,

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.